Product Datasheet

Avotaciclib


Catalog No. **BP-02287** · CAS **1983983-41-0** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-11-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
CDK; Apoptosis	**Cancer**

Molecular formula	**$C_{13}H_{11}N_7O$**
Molecular weight	**281.2727**

STRUCTURE



DESCRIPTION

Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer.

BIOLOGICAL ACTIVITY

Avotaciclib (0-64 μM; 48 h) can inhibit cell proliferation and promote apoptosis in radiotherapy-resistant non-small cell lung cancer cell lines, and the effect is better when combined with PV-1019

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1].Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

[2].Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17(2): 100900.